ArticleJournal of cancer research and clinical oncology2011
Efficacy control of therapy using circulating epithelial tumor cells (CETC) as "liquid biopsy": trastuzumab in HER2/neu-positive breast carcinoma.
Article in Journal of cancer research and clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- Review
- Circulating microRNA panels for multi-cancer detection and gastric cancer screening: leveraging a network biology approach.BMC medical genomics · 2025Article
- The human volatilome meets cancer diagnostics: past, present, and future of noninvasive applications.Metabolomics : Official journal of the Metabolomic Society · 2024Review
- High depletion of breast cancer cells from the peripheral blood with the method of non-specific separation.Ecancermedicalscience · 2020Article
- liqDB: a small-RNAseq knowledge discovery database for liquid biopsy studies.Nucleic acids research · 2019Article
- The Value of Monitoring the Behavior of Circulating Tumor Cells at the End of Endocrine Therapy in Breast Cancer Patients.Cancers · 2018Article
- Estrogen receptor-α promoter methylation is a biomarker for outcome prediction of cisplatin resistance in triple-negative breast cancer.Oncology letters · 2018Article
- Novel Strategies on Personalized Medicine for Breast Cancer Treatment: An Update.International journal of molecular sciences · 2017Review
- Article
- Establishment and Application of Prostate Cancer Circulating Tumor Cells in the Era of Precision Medicine.BioMed research international · 2017Review
- Quantification of rare cancer cells in patients with gastrointestinal cancer by nanostructured substrate.Translational oncology · 2014Article
- Circulating tumor cells in breast cancer.Journal of carcinogenesis · 2014Review
- Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer.Cancer medicine · 2013Article
- Dielectrophoresis has broad applicability to marker-free isolation of tumor cells from blood by microfluidic systems.Biomicrofluidics · 2013Article
- Article
- Heterogeneity of ERα and ErbB2 Status in Cell Lines and Circulating Tumor Cells of Metastatic Breast Cancer Patients.Translational oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe majority of targeted personalized cancer therapies are effective only in part of the patients, and most of these drugs are excessively expensive. Therefore, methods are urgently required, which reveal already early during treatment, whether the therapy is effective. In the present report, monitoring of circulating epithelial tumor cells (CETC) was used as a timely control of trastuzumab therapy in patients with HER2/neu-positive breast cancer.
methodsSeventy-nine sequential HER2/neu-positive breast cancer patients, 35 without trastuzumab, and 36 treated with 1 year of trastuzumab treatment were included. CETC from unseparated white blood cells stained with FITC-anti-EpCAM were analyzed repeatedly during chemotherapy and between 2 and 10 times during 1 year of maintenance treatment or observation.
resultsPatients treated with trastuzumab had a better relapse-free survival than patients without trastuzumab treatment during the first 2-4 years of follow-up. Decrease in numbers or no change versus highly variable numbers or increase (fivefold or more) allowed to discriminate highly significantly and clearly (P < 0.0001, hazard ratio 5.5) between patients with a low or high risk of relapse. An increase in CETC was accompanied by an increasing portion of cells containing a very high number of HER2/neu gene amplificates.
conclusionsAnalysis of the behavior of CETC can, in the future, contribute to evaluate the efficacy of targeted therapy early during the course of the disease, sparing patients unnecessary treatment but also to reduce the costs for the health system and to downsize the extent and length of clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.